Funding for the four UK Diagnostic Evidence Co-operatives (DECs), which were set up by the National Institute for Health Research (NIHR) in 2013, is coming to an end at the close next year. That means a restructuring of the activities and new methods of funding are imminent.
UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure
Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.
More from United Kingdom
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
• By
Medtech Insight sat down with Anja Streicher, chief marketing officer at Women of Wearables, a global community offering events and education resources to support the femtech industry, to discuss trends in the women's wearables tech market, challenges and innovators pushing the boundaries.
• By
Britain’s medtech system progress, smarter ways of working at the agency and getting smarter AI and digital technologies into circulation for patients, were themes woven through the UK MHRA board’s 18 March meeting.
• By
Wearable technology must address women’s unique needs, said Anja Streicher, Women of Wearables chief marketing officer. Samphire Neuroscience and Amira Health demo wearable solutions for PMS and hot flashes at Wired Health.
More from Europe
• By
As deadlines approach, the regulatory landscape for medtech batteries is set to change, with an emphasis on sustainability and ethical practices.
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
• By
The urine-based GAGome test showed promise in the first clinical results from the international AURORAX-0087A, in the largest study conducted on clear cell renal cell carcinoma, the most common type of kidney cancer.